eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2023
vol. 48
 
Share:
Share:
abstract:
Review paper

Molecular regulatory mechanism of LILRB4 in the immune response

Haiyin Liu
1, 2, 3
,
Jun Yang
1, 2
,
Jing Zhang
2, 3
,
Peiyue Zhang
1, 2, 3
,
Mengting Zhang
1, 2, 3
,
Chaojun Yang
2, 3
,
Li Liu
2, 3
,
Cuiyuan Huang
3
,
Wei Wang
2, 3
,
Yuhong Zhai
1, 2, 3
,
Jian Yang
1, 2

  1. Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yichang, China
  2. Institute of Cardiovascular Diseases, China Three Gorges University, Yichang, China
  3. HuBei Clinical Research Center for Ischemic Cardiovascular Disease, Yichang, China
Cent Eur J Immunol 2023; 48 (1): 43-47
Online publish date: 2023/02/23
View full text Get citation
 
PlumX metrics:
Immune diseases are caused by the imbalance of immune regulation. This imbalance is regulated by many factors, both negative and positive. Leukocyte immunoglobulin-like receptor B4 (LILRB4) is a member of leukocyte immunoglobulin-like receptors (LILRs). LILRs are expressed constitutively on the surface of multiple immune cells which associate with membrane adaptors to signal through multi- ple cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) or immunoreceptor tyro-sine-based activation motifs (ITAMs). Through ITIM, LILRB4 could recruit the src homology domain type-2-containing tyrosine phosphatase 1 or 2 (SHP-1 or SHP-2) into the cell membrane. In addition, many factors can induce the expression of LILRB4, such as vitamin D, interferon and so on. Studies have demonstrated that LILRB4 had a negative regulatory role in various of immune diseases. The present review intends to expound the structure and function of LILRB4, as well as its regulators and receptors in the immune cells, so as to provide a theoretical basis for immune disease therapy.
keywords:

LILRB4, SHP-1, immune disease, molecular mechanism

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.